BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 ...

On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion. "Immediately upon close, this ...

BioMarin Pharmaceutical (BMRN) has been in focus after raising its 2026 revenue guidance to US$3.83b to US$3.93b and sharing new VOXZOGO data that broaden attention on the drug’s health impact beyond ...

Investors in BioMarin Pharmaceutical Inc (Symbol: BMRN) saw new options begin trading today, for the July 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Fintel reports that on May 19, 2026, Citigroup initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a Buy ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the ridiculously cheap stocks to buy now. As of December 26, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has a ‘Buy’ rating from 74% of the analysts ...

Investors in BioMarin Pharmaceutical Inc (Symbol: BMRN) saw new options become available today, for the August 2026 expiration. One of the key data points that goes into the price an option buyer is ...